Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer

Published:2013-10-14 Issue:10 Volume:8 Page:e76169
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lin Jianzhong,Wu Hongfei,Shi Hui,Pan Wei,Yu Hongbo,Zhu Jiageng

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Cancer statistics, 2007;A Jemal;CA Cancer J Clin,2007

2. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies;M Mimeault;Carcinogenesis,2006

3. Management of the spectrum of hormone refractory prostate cancer;NW Clarke;Eur Urol,2006

4. 20-year outcomes following conservative management of clinically localized prostate cancer;PC Albertsen;JAMA,2005

5. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles;K Tamura;Cancer Res,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer;Oncology Reports;2018-07-24

2. Role of miR-452-5p in the tumorigenesis of prostate cancer: A study based on the Cancer Genome Atl(TCGA), Gene Expression Omnibus (GEO), and bioinformatics analysis;Pathology - Research and Practice;2018-05

3. The role of propranolol as a radiosensitizer in gastric cancer treatment;Drug Design, Development and Therapy;2018-03

4. Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer;Medicine;2017-03

5. Gefitinib;Adverse Events and Oncotargeted Kinase Inhibitors;2017